Antitumor effects of glycolysis inhibitors monoiodoacetate and 2-deoxyglucose were studied on Lewis lung carcinoma model. Monoiodoacetate exhibited antitumor and antimetastatic activities, being not inferior of methotrexate (reference drug); however, the preparation also demonstrated high systemic toxicity. 2-Deoxyglucose exhibited only antitumor effect, while its antimetastatic activity did not differ from the result in the group without treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Korshunov DA, Korshunova ZV, Kondakova IV. Inhibitors of carbohydrate metabolism in cancer therapy. Vol. Med. 2016;14(1):3-7. Russian.
Korshunov DA, Petrova ZV, Kondakova IV. Antitumor targets in the glycolytic metabolism of malignant neoplasms. Vestn Ross. Onkol. Nauch. Tsentra. 2014;25(3-4):35-42. Russian.
Treshchalina EM, Zhukova OS, Gerasimova GK, Andronova NV, Garin AM. Guidelines for preclinical study of anticancer activity of drugs. Manual for Preclinical Studies of New Pharmacological Substances. Mironov AN, ed. Moscow, 2012. P. 640-654. Russian.
Amoedo ND. Obre E, Rossignol R. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. Biochim. Biophys. Acta. 2017;1858(8):674-685.
Cerella C, Dicato M, Diederich M. Modulatory roles of glycolytic enzymes in cell death. Biochem. Pharmacol. 2014; 92(1):22-30.
Granchi C, Minutolo F. Anticancer agents that counteract tumor glycolysis. ChemMedChem. 2012;7(8):1318-1350.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
Korshunov DA, Kondakova IV. Effect of anti-glycolytic agents on tumour cells in vitro. AIP Conference Proceedings. 2016;1760(1). doi: https://doi.org/10.1063/1.4960254.
Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M, Savaraj N, Lane AN, Lampidis TJ. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol. Cancer Ther. 2007;6(11):3049-3058.
Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front. Pharmacol. 2011;2:49. doi: https://doi.org/10.3389/fphar.2011.00049.
Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS. Broad targeting of resistance to apoptosis in cancer. Semin. Cancer Biol. 2015;35(Suppl):S78-S103. doi: https://doi.org/10.1016/j.semcancer.2015.03.001.
Chen XS, Li LY, Guan YD, Yang JM, Cheng Y. Anticancer strategies based on the metabolic profile of tumor cells: therapeutic targeting of the Warburg effect. Acta Pharmacol. Sin. 2016;37(8):1013-1019.
Yu L, Chen X, Wang L, Chen S. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy. Oncotarget. 2016;7(25):38 908-38 926.
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 165, No. 5, pp. 644-647, May, 2018
Rights and permissions
About this article
Cite this article
Korshunov, D.A., Klimov, I.A., Ivanov, V.V. et al. Glycolysis Inhibitors Monoiodoacetate and 2-Deoxyglucose as Antitumor Agents: Experimental Study on Lewis Lung Carcinoma Model. Bull Exp Biol Med 165, 695–697 (2018). https://doi.org/10.1007/s10517-018-4244-1
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10517-018-4244-1